6751-75-3Oc1cccc(O)c1BrUOLPZAPIFFZLMF-UHFFFAOYSA-N6751-75-3DTXSID00345488Warning
H302 (97.5%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Uses2-Bromoresorcinol is a key intermediate in the treatment of hepatitis C, specifically clopipvir hydrochloride, a pan-genotypic NS5A replication complex inhibitor that can be used in combination with sofosbuvir for the treatment of chronic hepatitis C in adults. Therefore, the development of 2-bromocatechol has a promising market prospect.
Loading…